Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Not yet recruiting Phase 4 Interventional

Sotatercept in the Treatment of Methamphetamine-Associated Pulmonary Arterial Hypertension

ClinicalTrials.gov ID: NCT07938294

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT07938294. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Nov 18, 2026, 5:12 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Methamphetamine-Associated PAH: Early Therapy With Sotatercept - Feasibility and Outcomes in Clinical Use Study (METH-FOCUS)

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The goal of this clinical trial is to find out whether sotatercept, an FDA-approved medication for people with pulmonary arterial hypertension (PAH), can improve health outcomes for people with PAH due to use of methamphetamine. The main question it aims to answer is whether sotatercept added to standard background therapy and addiction medicine services will improve treatment response as measured by: * Echocardiographic measurements of pulmonary hypertension * Change in 6-minute walk distance (6MWD) * Change in categorization of disease (World Health Organization Functional Class, WHO FC) * Quality of life improvements Participants will need to adhere to their standard PAH therapy as well as the prescribed sotatercept, as well as actively engaging with addiction medicine services. They will complete the following activities: * Physical exam * Labs including drug screening * Pulmonary function testing (PFT) * Exercise testing (6MWD) * Echocardiography * Right heart catheterization (RHC) * Questionnaires related to their disease Participants will be in the study for about six months.

Study identification

NCT ID
NCT07938294
Recruitment status
Not yet recruiting
Study type
Interventional
Phase
Phase 4
Enrollment
20 participants

Conditions and interventions

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Dec 1, 2026 (Estimated)
Primary completion
Sep 1, 2028 (Estimated)
Completion
Nov 30, 2028 (Estimated)
Last update posted
Nov 16, 2026

2026 – 2028

United States locations

U.S. sites
2
U.S. states
2
U.S. cities
2
Facility City State ZIP Site status
The Queen's Medical Center Honolulu Hawaii 96813 —
Oregon Health & Science University Portland Oregon 97239 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT07938294, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Nov 16, 2026 · Synced Nov 18, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.